Article ID Journal Published Year Pages File Type
5715911 Annals of Diagnostic Pathology 2017 15 Pages PDF
Abstract
The μ-bcr breakpoint connects exon 19 of BCR with ABL giving rise to the e19a2 transcript corresponding to the p230 fusion protein (micro-BCR breakpoint) which is rarely seen in chronic myeloid leukemia (CML) patients. Here we report three patients with p230 fusion protein presenting with different clinical presentations and diagnosed as CML-CP. These patients received Imatinib (tyrosine kinase inhibitor-TKI) and are still in remission.
Related Topics
Health Sciences Medicine and Dentistry Pathology and Medical Technology
Authors
, , , , , , , , ,